Further development of BI 1467335 was stopped due to the risk of drug interactions of the compound with monoamine oxidase (MAO)-B in NASH patients identified in another Phase I trial30,31. This evidence concerns the gene MAOB and metabolic dysfunction-associated steatohepatitis.